Bellevue Life Sciences Acquisition (BLAC) Competitors $0.69 -0.18 (-20.44%) As of 07/31/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock BLAC vs. IINN, BDMD, XAIR, INBS, DHAI, MHUA, BTCY, WOK, LYRA, and PAVMShould you be buying Bellevue Life Sciences Acquisition stock or one of its competitors? The main competitors of Bellevue Life Sciences Acquisition include Inspira Technologies OXY B.H.N. (IINN), Baird Medical Investment (BDMD), Beyond Air (XAIR), Intelligent Bio Solutions (INBS), DIH Holding US (DHAI), Meihua International Medical Technologies (MHUA), Biotricity (BTCY), WORK Medical Technology Group (WOK), Lyra Therapeutics (LYRA), and PAVmed (PAVM). These companies are all part of the "medical equipment" industry. Bellevue Life Sciences Acquisition vs. Its Competitors Inspira Technologies OXY B.H.N. Baird Medical Investment Beyond Air Intelligent Bio Solutions DIH Holding US Meihua International Medical Technologies Biotricity WORK Medical Technology Group Lyra Therapeutics PAVmed Inspira Technologies OXY B.H.N. (NASDAQ:IINN) and Bellevue Life Sciences Acquisition (NASDAQ:BLAC) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk. Which has more volatility & risk, IINN or BLAC? Inspira Technologies OXY B.H.N. has a beta of 2.29, suggesting that its stock price is 129% more volatile than the S&P 500. Comparatively, Bellevue Life Sciences Acquisition has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Is IINN or BLAC more profitable? Company Net Margins Return on Equity Return on Assets Inspira Technologies OXY B.H.N.N/A N/A N/A Bellevue Life Sciences Acquisition N/A N/A N/A Which has higher earnings & valuation, IINN or BLAC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInspira Technologies OXY B.H.N.N/AN/A-$11.05MN/AN/ABellevue Life Sciences AcquisitionN/AN/AN/AN/AN/A Do analysts rate IINN or BLAC? Inspira Technologies OXY B.H.N. currently has a consensus price target of $2.00, suggesting a potential upside of 62.60%. Given Inspira Technologies OXY B.H.N.'s stronger consensus rating and higher possible upside, research analysts clearly believe Inspira Technologies OXY B.H.N. is more favorable than Bellevue Life Sciences Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inspira Technologies OXY B.H.N. 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Bellevue Life Sciences Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of IINN or BLAC? 12.7% of Inspira Technologies OXY B.H.N. shares are owned by institutional investors. Comparatively, 55.3% of Bellevue Life Sciences Acquisition shares are owned by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are owned by company insiders. Comparatively, 33.7% of Bellevue Life Sciences Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor IINN or BLAC? In the previous week, Inspira Technologies OXY B.H.N. had 1 more articles in the media than Bellevue Life Sciences Acquisition. MarketBeat recorded 1 mentions for Inspira Technologies OXY B.H.N. and 0 mentions for Bellevue Life Sciences Acquisition. Inspira Technologies OXY B.H.N.'s average media sentiment score of 0.00 equaled Bellevue Life Sciences Acquisition'saverage media sentiment score. Company Overall Sentiment Inspira Technologies OXY B.H.N. Neutral Bellevue Life Sciences Acquisition Neutral SummaryInspira Technologies OXY B.H.N. beats Bellevue Life Sciences Acquisition on 5 of the 7 factors compared between the two stocks. Get Bellevue Life Sciences Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for BLAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLAC vs. The Competition Export to ExcelMetricBellevue Life Sciences AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$2.78M$212.91M$2.21B$9.53BDividend YieldN/A3.27%2.59%4.08%P/E RatioN/A1.9222.1423.80Price / SalesN/A560.2583.4188.08Price / CashN/A115.7726.0557.96Price / BookN/A8.9740.025.55Net IncomeN/A-$11.33M-$62.28M$259.03M7 Day Performance-29.78%-1.46%-2.44%-4.56%1 Month Performance-54.42%-1.34%-0.52%4.49%1 Year Performance-93.65%115.95%26.20%18.05% Bellevue Life Sciences Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLACBellevue Life Sciences AcquisitionN/A$0.69-20.4%N/A-93.6%$2.78MN/A0.00N/AGap UpHigh Trading VolumeIINNInspira Technologies OXY B.H.N.1.632 of 5 stars$1.35-2.5%$2.00+48.7%+10.8%$16.99MN/A0.0020BDMDBaird Medical InvestmentN/A$2.28+5.1%N/AN/A$15.01M$37.04M0.00N/AGap DownXAIRBeyond Air3.6802 of 5 stars$3.35-1.5%$23.67+606.5%-74.0%$14.47M$3.70M-0.2170Short Interest ↑High Trading VolumeINBSIntelligent Bio Solutions0.5622 of 5 stars$2.04-9.6%N/A+9.7%$14.06M$3.11M0.0010DHAIDIH Holding US0.5848 of 5 stars$0.29+10.9%N/A-91.5%$13.78M$64.47M-0.97N/ANews CoverageMHUAMeihua International Medical Technologies1.6085 of 5 stars$0.40-1.6%N/A-59.9%$12.82M$96.90M0.00620BTCYBiotricityN/A$0.49-4.6%N/A-40.4%$12.13M$12.06M-0.4540Gap UpWOKWORK Medical Technology GroupN/A$0.83+5.7%N/AN/A$12.02M$11.51M0.00226LYRALyra Therapeutics2.9764 of 5 stars$8.54+4.1%$100.00+1,071.0%-57.0%$11.32M$1.19M-0.1450Positive NewsPAVMPAVmed4.4264 of 5 stars$0.59+0.2%$19.00+3,125.8%-34.5%$10.07M$2.99M0.8390News CoveragePositive News Related Companies and Tools Related Companies IINN Competitors BDMD Competitors XAIR Competitors INBS Competitors DHAI Competitors MHUA Competitors BTCY Competitors WOK Competitors LYRA Competitors PAVM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLAC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellevue Life Sciences Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellevue Life Sciences Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLAC Stock Alerts